Exhibit 99.1

FOR FURTHER INFORMATION CONTACT:

Sophia H. Twaddell
Vice President, Corporate Communications
(847) 864-3500
stwaddell@northfieldlabs.com

FINAL
NOT FOR IMMEDIATE RELEASE

NORTHFIELD LABORATORIES NAMES
VICE PRESIDENT FINANCE

EVANSTON, IL—July 28, 2006— Northfield Laboratories Inc. (Nasdaq: NFLD) announced today it has appointed John J. Hinds as Vice President Finance, reporting to Steven A. Gould, M.D., Chairman and Chief Executive Officer. Mr. Hinds will serve as the Company’s principal financial and accounting officer. He will begin his duties at Northfield on August 14, 2006.

Mr. Hinds brings more than 18 years experience in finance and accounting in both public and private companies to his position at Northfield. He has had extensive experience in the financial control of rapid growth companies. Prior to joining Northfield, Mr. Hinds served as Vice President Finance, Products at Bowe Bell + Howell. In that position, he was responsible for financial and shared service functions, including information services, as well as supply chain management. Prior to that position, Mr. Hinds served as Senior Finance Manager, Gateway, Inc. and as Business Unit Controller at Baxter Healthcare Corporation. Mr. Hinds began his career at Deloitte & Touche.

Mr. Hinds holds B.S. in Accounting from DePaul University and is a C.P.A.

Jack J. Kogut, who previously served as the Company’s Senior Vice President Finance, will assume the title of Senior Vice President Administration.

About Northfield Laboratories

Northfield Laboratories Inc. is a leader in developing an oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss, when an oxygen-carrying fluid is required and red blood cells are not available. PolyHeme^® is a solution of chemically modified human hemoglobin that requires no cross matching and is therefore compatible

1560 Sherman Avenue, Suite 1000, Evanston, IL 60201-4800 Tel: 847-864-3500

with all blood types. It has a shelf life in excess of 12 months. Enrollment is currently underway in a pivotal Phase III trial of PolyHeme^® beginning in the pre-hospital setting. For further information, visit www.northfieldlabs.com.

This press release may contain forward-looking statements concerning, among other things, Northfield’s future business plans and strategies and clinical and regulatory developments affecting our PolyHeme^® red blood cell substitute product. These forward-looking statements are identified by the use of such terms as “intends,” “expects,” “plans,” “estimates,” “anticipates,” “should,” “believes” and similar terms. These forward-looking statements involve inherent risks and uncertainties. Our actual results may therefore differ materially from those predicted by the forward-looking statements because of various factors and possible events, including our ability to obtain FDA approval to market PolyHeme commercially, the availability of capital to finance our clinical trials and ongoing business operations, our ability to obtain adequate supplies of raw materials and to manufacture PolyHeme in commercial quantities, our ability to market PolyHeme successfully, the possibility that competitors will develop products that will render PolyHeme obsolete or non-competitive, our ability to protect our intellectual property rights, the outcome of certain governmental inquiries and purported class action lawsuit as described in our most recently filed quarterly report on Form 10-Q, the possibility that we may be subject to product liability claims and other legal actions, our dependency on a limited number of key personnel, the uncertainty of third party reimbursement for our product and other risks and uncertainties described from time to time in our periodic reports filed with the Securities and Exchange Commission, including our most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. These forward-looking statements speak only as of the date of this press release. We do not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the time such statement is made. All subsequent written and oral forward-looking statements attributable to Northfield or any person acting on our behalf are qualified by this cautionary statement.

1560 Sherman Avenue, Suite 1000, Evanston, IL 60201-4800 Tel: 847-864-3500